{"disease":{"id":"relapsed-refractory-b-cell-lymphomas","name":"relapsed refractory b cell lymphomas"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06561425","title":"A Study Evaluating the Safety and Efficacy of GLPG5101 (19CP02) in Participants With Non-Hodgkin Lymphoma","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":130,"lead_sponsor_name":"Galapagos NV","has_results":false},{"nct_id":"NCT06478381","title":"L218CAR19 in Patients With Relapsed/Refractory B-cell Lymphoma","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":22,"lead_sponsor_name":"Henan Cancer Hospital","has_results":false},{"nct_id":"NCT03576807","title":"The Clinical Research of Anti-CD20 CAR-T Cells in Patients With Refractory or Relapsed B Lymphocyte Lymphoma","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":20,"lead_sponsor_name":"Xin Wang","has_results":false},{"nct_id":"NCT04450069","title":"CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":18,"lead_sponsor_name":"Calibr, a division of Scripps Research","has_results":false},{"nct_id":"NCT04488354","title":"Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":16,"lead_sponsor_name":"Calibr, a division of Scripps Research","has_results":false},{"nct_id":"NCT02271945","title":"Safety/Efficacy of MEDI-551 in Combination With Immunomodulating Therapies in Subjects With Aggressive B-cell Lymphomas","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":10,"lead_sponsor_name":"MedImmune LLC","has_results":true}],"total":6},"guidelines":[],"source":"Drug Landscape verified database"}